Sully.ai vs CoverMyMeds
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF healthcare AutonomousOS automating clinical documentation and prior auth for hospitals; YC $30.5M Sequoia Scout/AUM Ventures Series A Jan 2025 competing with Nuance DAX and Abridge for AI-powered physician workflow automation.
About
Sully.ai is a San Francisco-based healthcare AI company — backed by Y Combinator with $30.5 to $32.1 million raised including a $21.83 million Series A in January 2025 from AUM Ventures, Leonis Capital, SemperVirens VC, and Sequoia Scout Fund — providing hospitals, physician practices, and health systems with an AutonomousOS platform that automates clinical documentation (ambient AI scribing that generates SOAP notes from patient-physician conversations), administrative workflows (prior authorization processing, insurance eligibility verification, scheduling automation), and revenue cycle management tasks that consume 30-40% of physician time and hospital administrative labor. Founded in 2023 by Ahmed Nasser and Ahmed Omar, Sully.ai has 49 employees and serves healthcare providers globally with AI agents that autonomously execute multi-step clinical and administrative processes without requiring physician or staff intervention.
Largest prior authorization network in the US connecting 75K+ pharmacies, 750K+ providers, and all payers. Columbus OH; acquired by McKesson; available free to providers and pharmacies; processes millions of PA requests annually for specialty and retail prescriptions at no provider cost.
About
CoverMyMeds is the largest prior authorization platform in the United States, operating a network that connects more than 750,000 providers, 75,000 pharmacies, and virtually all payers to streamline the authorization process for prescription medications. Founded in 2008 in Columbus, Ohio, and acquired by McKesson Corporation in 2017, CoverMyMeds processes millions of prior authorization requests annually and has become foundational infrastructure for the US pharmacy and specialty medication market. The platform is available at no cost to providers and pharmacies and is funded through health plan and PBM partnerships.\n\nCoverMyMeds' network effect is central to its value: because the platform is used by the vast majority of pharmacies and a very large share of prescribing providers, payers can reach their entire provider and pharmacy network through a single connection. The platform supports real-time benefit checks that show the formulary status and prior authorization requirements for a drug at the point of prescribing, enabling providers to make more informed prescribing decisions before a patient reaches the pharmacy counter. Automated electronic prior authorization (ePA) workflows reduce approval times from days to hours for eligible drug-payer combinations.\n\nAs part of McKesson, CoverMyMeds has expanded its capabilities to include specialty medication access solutions, patient assistance program enrollment, and medication adherence tools. The company's RxCrossroads subsidiary provides hub services for specialty pharmaceutical manufacturers, creating a comprehensive access ecosystem that spans from initial authorization through patient support and adherence management.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.